Orna Therapeutics
PrivateLast Round
Series B
Aug 16, 2022
Total Funding Raised
$321M
Company Overview
Orna Therapeutics is a biotechnology company that develops a new class of fully engineered circular RNA (oRNA) therapeutics. The company's proprietary platform combines oRNA technology, which offers advantages over traditional linear mRNA such as greater stability and protein expression, with lipid nanoparticle (LNP) delivery systems. Orna aims to create in vivo therapies to treat a range of diseases, with a focus on oncology, autoimmune diseases, and genetic disorders. In May 2024, Orna acquired ReNAgade Therapeutics to incorporate its RNA delivery systems and editing programs. The company's lead programs include an in situ CAR (isCAR) therapy for cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Orna Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Orna Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 16, 2022 | ||||
| Series A | Feb 24, 2021 | ||||
| Seed | May 11, 2020 |
Key People
Founding team and executive leadership
Orna Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MPM Capital | Series B, Seed, Series A |
| Taiho Ventures | Series A |
| MPM BioImpact | Series B |
| PAG | Series A |
| Astellas Venture Management | Series A |
| F2 Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 11, 2026
ORN-252 targets CD19 for autoimmune diseases.
- Dec 7, 2025
New preclinical data for in vivo CAR programs presented at ASH Annual Meeting.
Orna Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Orna Therapeutics's valuation, stock price, and market status.
